Poniard Pharmaceuticals to Present at the BIO CEO & Investor ... ( SOUTH SAN FRANCISCO Calif. Feb. 3...)

Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference

Date:2/3/2009

SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the 11th Annual BIO CEO & Investor Conference 2009 on Tuesday, February 10, at 10 a.m. Eastern Time at the Waldorf-Astoria in New York.

Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration resistant prostate cancers (also known as hormone refractory prostate cancer), as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit h
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/2/2009)...Gabon, December 2 , - "Bo...m and Heritage" , Coinciding with the Int...,Gabonese Republic is hosting an international con...guarding biological resources in Africa. The,confe...ders, ministers,scientific experts, private compa...

(Date:12/2/2009)...Mass., Dec. 2 TechConnect World, a...y development and product integration in cleantech...er 11th deadline for technology abstracts and busi...chConnect World, in association with the Nano Scie... Technology and Sustainable Industries Organizatio...

(Date:12/2/2009)...Dec. 2 S*BIO Pte Ltd today announc...itor, SB1518, at The American Society of Hematolog...s. ,, Data will be presented on the clinical re...1518 detailing its safety, tolerability and pharma...levels ranging from 100 to 600 mg. These doses wer...

(Date:12/2/2009)...hina, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmace... SCR ), a leading pharmaceutical company,specializ...ng of branded,generic and proprietary pharmaceutic...s have been included in China,s National Drug Reim...,s Ministry of Human Resources and Social,Security...

Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2 Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2 Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3 S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2 S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3 S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4 S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5 Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2 Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3

[0] Libreville International Conference 2-3 June 2010 [0] Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies [0] S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders [0] Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List

..., Human plasma and serum represents an impo...iagnosis. However, the wide dynamic range in prote...nge in the development of diagnostic assays for ,...roteins in the presence of high , abundan... to remove 99% , of the diagnostically un...

...acy Worzella and Brad Larson , Promega Co... , Application Note 139 ... , Multiplexing homogeneous cell-based a...ers from a single sample well , Monitoring... Assay miniaturization up to 1536-well format...

...rjan Orban 1 , Francois Degorce 2 and Jean-Luc ,...many; 2 Cisbio international, France , ... , Rev. 12/2005 , ...pathway investigation under HTS conditions , ...r with the HTRF , IP-One assay in terms...

Protein Depletion for Plasma and Serum Proteomic Analysis Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar HTRF IP-One Assay Performed on the PHERAstar and RUBYstar Plate Readers

(Date:12/3/2009)...a personality change in warmer water, according to...hange may make some species more aggressive. , E... Australia,s Great Barrier Reef have shown for the...ently timid, or consistently bold, and that these ...er temperatures rise. , A slight lift of just on...

(Date:12/3/2009)...it comes to investment in energy efficient technol...ces Research Council (EPSRC) Chief Executive Dave ...d engineering research has already brought us fuel...t more investment is needed to develop the capabil... carbon emission targets by 2020 and limit the imp...

(Date:12/2/2009)...turated Latino men have a more difficult time quit...to U.S. culture, but acculturation has no affect o...se findings are published in Cancer Epidemiology,...an Association for Cancer Research. The December i...ation affects smoking cessation differently for La...

Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2 Research is vital to a cleaner, greener, low carbon future 2 Acculturation affects smoking cessation success among Latinos 2 Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 1 Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 2 Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 3 Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 4 Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 5 Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 6 Survey Finds AARP Members Back Health Care Reform Legislation 61472 1 Survey Finds AARP Members Back Health Care Reform Legislation 61472 2 Gen Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts 14858 1 Gen Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts 14858 2

[0] Fish with attitude: Some like it hot [0] Research is vital to a cleaner, greener, low carbon future [0] Acculturation affects smoking cessation success among Latinos

...he molecular machines that drive all life, also sh...he study, in the journal Structure , reveals that...y experienced a "big bang" of innovation. The acti...ned with each other or split apart to produce a ho...This explosion of new forms coincided with the rap...

...s animals of the Americas avoid competing for the ...ssible answer comes from a new study by a pair of .... Their large-scale analysis shows that it,s not j...s themselves that have been a driving force in the...ctors as whether species are active daytime or nig...

..., 2009)Attempts to treat critical limb ischemia in...elow-the-knee angioplasty are still thwarted by re...te of angioplasty or stenting), the need for repea...rosclerotic disease, leading to tissue death (gang...have been studying a potential solutionthe use of ...

Other Biology News:Study of protein structures reveals key events in evolutionary history 2 American carnivores evolved to avoid each other, new study suggests 2 Promising 3-year data: Saving limbs with drug-eluting stents 2 Promising 3-year data: Saving limbs with drug-eluting stents 3

Study of protein structures reveals key events in evolutionary history American carnivores evolved to avoid each other, new study suggests Promising 3-year data: Saving limbs with drug-eluting stents

Fluorescent Standards Green Standard from Invitrogen

Customized Competent E. coli. from Molecular Cloning Laboratories (MCLAB)

X-Gal from BIOPUR

Mouse Anti-Oligodendrocyte Marker O1 Monoclonal Antibody, Unconjugated, Clone O1 from R&D Systems

Biology Products:

Fluorescent Standards Green Standard from Invitrogen Customized Competent E. coli. from Molecular Cloning Laboratories (MCLAB)X-Gal from BIOPUR Mouse Anti-Oligodendrocyte Marker O1 Monoclonal Antibody, Unconjugated, Clone O1 from R&D Systems

Poniard Pharmaceuticals to Present at the BIO CEO & Investor ...( SOUTH SAN FRANCISCO Calif. Feb. 3...)